证券时报见习记者 沈述红 "市场正在经历一场创新驱动的牛市。"近日，民生加银基金权益投资部总监助理、投资决策委员会成 员、基金经理尹涛接受证券时报记者采访时表示，当前AI、创新药、新消费等领域正在爆发"中国式创 新"的化学反应。 这位兼具10年财经媒体观察视角与17年跨市场投资经验的管理人，通过构建"宏观周期研判+行业轮动 配置+个股深度挖掘"的三维模型，在近年结构性市场中形成差异化投资策略。尹涛提出，"要学会在牛 市打'持久战'，在平衡市和熊市打'游击战'，让'基本面'与'活下去'同频"。 以宏观为锚 作为中国最早一批证券市场守望者，尹涛深耕行业27载，前10年投身财经媒体，后17年专注证券投资领 域。由于媒体生涯经常面对面接触发改委和财政部的高层官员与专家，他在这段经历中练就了独特 的"政策破译能力"，建立起宏观研究的视野。这为他日后转型投资奠定了基础。 2008年，尹涛加入长城人寿保险投资部，担任投资经理。当时保险资管行业尚处萌芽阶段，投资工具、 人手和范围均有限制。但正是这种"戴着镣铐跳舞"的环境，练就了他的大类资产配置能力。 2008年全球金融危机期间，市场在恐惧与贪婪中剧烈波动。尹涛判断国内通胀将 ...

Core Viewpoint - The market is experiencing an innovation-driven bull market, with sectors such as AI, innovative pharmaceuticals, and new consumption witnessing significant growth in "Chinese-style innovation" [1][6]. Group 1: Investment Strategy - The investment strategy is based on a three-dimensional model combining macroeconomic cycle assessment, industry rotation allocation, and in-depth stock analysis [1][4]. - The approach emphasizes a dynamic balance in asset allocation, avoiding extreme positions typical of either growth or value investing [4][5]. - The investment framework is characterized by a focus on economic cycles and industry trends, selecting 3 to 5 high-prospect industries for targeted investment each year [4][6]. Group 2: Performance Metrics - The net value growth rate of the fund managed by the company reached 19.18% in the past six months and 18.70% over the past year [3]. - The fund's performance ranked in the top 5% of its peers over the past two years, indicating strong relative performance [3]. Group 3: Market Adaptation - The company adjusts its stock positions flexibly, reducing equity exposure from 91% in Q2 2023 to 67% by the end of Q4 2023, effectively managing drawdowns during uncertain market conditions [6]. - In 2024, the company increased stock positions again, successfully capturing market opportunities [6]. Group 4: Key Investment Themes - The company identifies three key investment themes with contemporary relevance: AI, innovative pharmaceuticals, and new consumption, which are seen as driving forces of the current market [5][6]. - The innovative pharmaceutical sector is highlighted as undergoing significant transformation, approaching the standards of developed countries [6].